Doctors highlighted that with the right treatment, workplace support and careful planning, cancer patients can return to work and rebuild their professional lives

FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumour growth in more than 90 per cent of pancreatic cancer cases. It's an approach that previously eluded drugmakers for decades